Our internationally renowned clinical microbiology laboratories offer a broad selection of tests designed for rapid identification and in-depth characterization of the causative agents of infectious diseases. We have developed and implemented culture techniques, immunoassays, antimicrobial susceptibility testing, and molecular methods for rapid detection, identification, and characterization, as well as provision of treatment guidance for microbial pathogens.
“We're always trying to develop new methods, broader methods, faster methods, less expensive methods.”
Nancy Wengenack, Ph.D., Division of Clinical Microbiology
Our difference
The latest
William Morice II, M.D., Ph.D., recently joined the Advisory Board for a webinar discussion on 2024 lab market trends. Dr. Morice covered the current lab market outlook, the priority trends, and opportunities for future growth.
Mayo Clinic Laboratories now offers a noninvasive approach for the molecular detection of H. pylori, with results that include prediction of clarithromycin resistance delivered within 24 hours.
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Genitourinary Pathology.
In this month’s Hot Topic, Robin Patel, M.D., discusses Mayo Clinic Laboratories’ new PCR assay for detection of Helicobacter pylori detection and determination of clarithromycin resistance directly from stool.
Thank you to our staff at Mayo Clinic who step up daily during this time of need to provide access to testing during the global pandemic. We appreciate each one of you and all the sacrifices you personally have made throughout this past year.
Dr. Patel, director of Mayo Clinic's Infectious Diseases Research Laboratory, discussed the future of testing for joint and bone infections.
Nancy Wengenack, Ph.D. gives an overview of this test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken due to the results of this testing.
In this month’s “Hot Topic,” Elitza Theel, Ph.D., talks about Mayo Clinic Laboratories’ serologic and molecular testing for the identification of infection with dengue virus. Dengue virus poses a significant public health threat worldwide. Rapid and accurate identification of the infection enables directed monitoring of patients who may be at increased risk of developing hemorrhagic fever of dengue shock syndrome.
Leading the charge to help educate and find solutions to the antimicrobial resistance crisis is Robin Patel, M.D., as she recently served on a congressional briefing panel.
Matthew Binnicker, Ph.D., Director of the Clinical Virology Laboratory in the Division of Clinical Microbiology at Mayo Clinic, recently spoke with Consultant360 regarding testing for viral gastroenteritis.
Elitza Theel, Ph.D., Director of the Infectious Diseases Serology Laboratory, discusses eastern equine encephalitis virus, which is spread via mosquito bite.
In this month’s “Hot Topic,” Elitza Theel, Ph.D., will discuss the detection of (1→3)-β-D-glucan (BDG) in serum as a biomarker for the presence of invasive fungal infections.
Antimicrobial susceptibility testing determines whether these bacteria are susceptible or resistant to a particular antibiotic. Bacteria are added onto plates of solid agar, where each plate has a different and increasing concentration of antibiotic than the previous plate. The minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial that inhibits growth of the bacteria.